InSCREENex GmbH

CHO-Nav1.7

Nav1.7 CHO Stable Recombinant Cell Line

This Nav1.7 cell line is a recombinant clonal stable CHO cell line expressing full length human Sodium channel protein type 9 subunit alpha (SCN9A aka Nav1.7). Electrophysiological characterization was performed by Metrion Biosciences. Detailed information and characterisation can be found in the Product Sheet.

Target Aliases

PN1, ETHA, NENA, Nav1.7, SCN9A

Cell Background

CHO-K1 (Chinese Hamster Ovary), epithelial-like cells, adherent but can be transferred into suspension.

Buying and Ordering the Cells

For non-profit organizations, cells are available for perpetual academic research under the Limited Research Use License.

For-profit entities can purchase cells for perpetual commercial use under the Limited Commercial Use License.

To request a quote, please email us at or use the contact form provided below.

We are already registered on several digital order processing platforms, if you would like to add us as a registered supplier, please contact us at and we are happy to help.

Supplied as

Each license includes 2 vials of >2Mio viable cells. Additional or replacement vials can be purchased for a fee of 450€.

Catalog Number
INS-SF-1037
Features and Applications
  • Nav1.7 expression
  • CHO Background
  • Electrophysiological validation
Price Non-Profit (Academic Research)
Inquire
Price For-Profit (Commercial Use)
Inquire
Product Sheet
Limited Research Use License
Limited Commercial Use License

Target Info

Background

Nav1.7 (also known as SCN9A) is a voltage-gated sodium channel primarily expressed in peripheral sensory neurons, where it plays a critical role in the transmission of pain signals. By controlling the influx of sodium ions, Nav1.7 contributes to the generation and propagation of action potentials, making it a key mediator of nociceptive signaling. Genetic studies have highlighted the significance of Nav1.7 in pain regulation. Loss-of-function mutations in the SCN9A gene result in congenital insensitivity to pain, while gain-of-function mutations are linked to chronic pain syndromes, such as inherited erythromelalgia. This establishes Nav1.7 as a highly promising therapeutic target for pain management.

Field of Research

Product Details

Stable recombinant CHO cells at low and high confluency, cultured in CHO Growth Medium A (INS-ME-1039) as a 2D monolayer.

Extensive electrophysiological validation by Metrion Biosciences on the QPatch automated patch clamp platform. See the Product Sheet for more details.

ParameterNav1.7 CHO Cell Line
Expressed SubunitsSCN9A (α)
ExpressionConstitutive (CMV)
Patch Clamp PlatformsQPatch
TTX ResistanceNo (TTX-sensitive)
Peak Current Amplitude–5 nA
Activation V₀.₅–20.1 mV
Inactivation V₀.₅–71.9 mV
Seal Formation Success90%
Recording Success75%
Stability Over Time≥4 weeks in culture
Reference Compounds IC₅₀ values
(resting/inactivated)
TTX: 37 nM
PF-05089771: 14 nM
Tetracaine: 4.1 µM / 532 nM
Amitriptyline: 16 µM / 1.8 µM

We recommend the following reagents for the cell culture of this cell line:

Growth Medium: CHO Growth Medium A (INS-ME-1039)

Freezing Medium: Cell Freezing Medium (INS-SU-1027)

Coating: not required

  • Product Sheet including all relevant protocols and instructions (PDF)
  • Material Safety Data Sheet (PDF)
  • Request CoA (Email)

Coming Soon!

Stay tuned for comprehensive protocols for this cell line, from routine cell cultures to assay manuals.

Related Products

Medium for cryopreservation of immortalized and stable cells.

  • Cryopreservation Medium
  • Ready-to-use
  • 30ml
More details
and prices 🠆

Ready-to use Medium for culture of CHO cells (Type-A).

  • CHO culture (Type-A)
  • Ready-to-use
  • 500ml
More details
and prices 🠆

Nav1. 8 expressing CHO recombinant stable cell line.

  • Nav1.8 expression
  • CHO Background
  • Electrophysiological validation
More details
and prices 🠆

Product FAQ

What cell background is used for these models?

Both the Nav1.7 and Nav1.8 cell lines are based on a proprietary CHO-K1-derived landing pad cell line developed by inscreenex. This platform allows site-specific, single-copy integration and supports stable, high-level expression in both adherent and suspension formats.

Yes. The Nav1.7 and Nav1.8 cell lines were validated on the Sophion QPatch platform, and Nav1.8 was additionally tested on the Qube system. Both cell lines demonstrated high seal formation and recording success rates, confirming suitability for automated workflows.

Each cell line is accompanied by a comprehensive data package including:

  • Peak current amplitudes

  • Activation and inactivation V₀.₅ values

  • Pharmacological IC₅₀ values for reference compounds

  • Recording success rates on automated systems

All data were generated by Metrion Biosciences Ltd, a leading CRO in ion channel electrophysiology.

es. The Limited Commercial Use License (LCUL) permits CROs to use the cells:

  • Under contract with a licensed client, or

  • Through direct licensing to offer fee-for-service work to third parties

Yes. inscreenex offers:

  • Gain- and loss-of-function mutants for Nav1.7 and Nav1.8 (e.g., IEM, PEPD, CIP)

  • Species-specific orthologs (mouse, rat, dog, Cynomolgus monkey)

All custom models are built using the same CHO landing pad platform.

Each order includes:

  • Two cryopreserved vials of the selected cell line (additional vials available for a service fee)

  • Detailed protocols for thawing, freezing, culture (adherent and suspension)

  • Patch clamp solution compositions and voltage protocols

Yes, both Nav1.7 and Nav1.8 cell lines are in stock and usually ship within 1–2 business days.
Estimated shipping times:

  • EU: 1–2 business days

  • UK: 2–3 business days

  • USA: 3–4 business days

  • Rest of world: please contact us for estimated delivery timelines

The cell lines are BSL1.

Cells are available for commercial use under a Limited Commercial Use License (LCUL).

This license permits:

  • Use by for-profit entities for internal drug discovery and development

  • Use by CROs, either under contract with the licensee or via direct licensing

For any other commercial uses (resale, batch-release, manufacturing etc.) , please contact our Out-Licensing Team.

The cells are available under a one-time access fee, with no royalties or ongoing costs. Pricing includes two vials and the full licensing and protocol package. A discounted introductory offer is available when both cell lines are purchased together.

Literature and Reference

No research papers published yet.

 

We love to hear about your research! Please let us know if you have published using our cells.